Daehan New Pharm, Simultaneous Growth in Sales and Profits of 'Health Functional Pharmaceuticals'

Published 13 Aug.2021 13:19(KST)

[Asia Economy Reporter Lim Jeong-su] Daehan New Pharm, a KOSDAQ-listed company known for its health functional pharmaceutical products, continued its steady performance growth in the first half of this year.

Daehan New Pharm announced on the 13th that it achieved a cumulative operating profit of 13.9 billion KRW in the first half of this year, marking a 13% increase compared to the same period last year. Sales rose 13% to 83.8 billion KRW, and net profit also increased by 19% to 8.9 billion KRW.

The company also posted strong results for the second quarter. Sales for Q2 reached 44.2 billion KRW, up 14% from the same period last year. Operating profit increased by 8% to 7.2 billion KRW. Net profit for the second quarter alone was 4.7 billion KRW, a 22% increase.

Daehan New Pharm explained that its strategy of focusing sales on key core product lines was effective. The company evaluated positively the sales growth of well-being injections such as ‘Liporajeju’, immune boosters like ‘Thymosin Injection’ and ‘Vitadi Injection’, as well as new products including the dyslipidemia combination drug ‘Nutoget’, fat absorption inhibitor ‘Zerobi’, and the domestically exclusive carbohydrate absorption inhibitor ‘Migbos Film-Coated Tablets’.

In the second half of this year, Daehan New Pharm plans to launch a health functional food brand called ‘DiNU’. With the slogan of being the most ideal health functional food focused on functionality based on the identity of a pharmaceutical company, new products will be sequentially released starting from the end of August.

A Daehan New Pharm official stated, "Sales of injections and new products are growing steadily," adding, "We plan to actively promote the newly launched ‘DiNU’ to successfully establish it in the market and contribute to sales growth." The official also said, "The Central Research Institute and Bio Research Institute have relocated to the Pangyo Industry-Academia-Research Center to strengthen our pipeline," and added, "We will continue to develop as a research and development-focused company."